SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.

Front Pharmacol · 2022 · PMC9626527 · PMID 36339534

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

) combined with dual antiplatelet drugs showed a trend of reducing thrombotic events (not statistically significant), but it was also accompanied by an increased risk of bleeding, which was limited in clinical application ( Lou et al., 2018 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.